 Home > Encyclopedia > Enoxacin gluconate

Enoxacin gluconate

Enoxacin gluconate structure

CAS No:
104142-71-4
Formula:
C15H17FN4O3.xC6H12O7
Chemical Name:
Enoxacin gluconate
Synonyms:
D-Gluconic acid,compd. with 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid (1:?);D-Gluconic acid,compd. with 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid;Enoxacin gluconate
Categories:
Active Pharmaceutical Ingredients > Synthetic Anti-infective Drugs

Request for Quotation

Enoxacin gluconate Basic Attributes

Molecular Weight：

534.491

Exact Mass：

534.19700

Characteristics

PSA：

235.14000

XLogP3：

-2.50030

Drug Function and Efficacy

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. The antibacterial activity against anaerobic bacteria is poor. Enoxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Enoxacin Gluconate for Injection
Ingredients	The main ingredient of this product is enoxacin gluconate. Its chemical name is: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid-D-gluconate monohydrate.
Indication	1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the elimination of theophylline in the liver, a prolonged elimination half-life (t1/2), an increase in blood concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., so it should be avoided to use it in combination. If it cannot be avoided, the blood concentration of theophylline should be measured and the dose should be adjusted. 3 When cyclosporine is used in combination with this product, its blood concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter, so the combination of the two should be avoided. If it cannot be avoided, the patient's prothrombin time should be closely monitored and the dose adjusted. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6 This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (t1/2), and possible central nervous system toxicity, so the two should be avoided in combination. If it cannot be avoided, the patient's blood caffeine concentration should be closely monitored and the dose adjusted. 7 Antacids containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together. 8 When this product is used in combination with the non-steroidal anti-inflammatory drug fenbufen, convulsions occasionally occur, so it should not be used in combination with fenbufen.
Specifications	0.2g (based on enoxacin)
Manufacturer	Harbin Medisan Pharmaceutical Co., Ltd.

Enoxacin Gluconate for Injection
Ingredients	The main ingredient of this product is enoxacin gluconate. Its chemical name is: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid-D-gluconate monohydrate.
Indication	1 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2 When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the elimination of theophylline in the liver, a prolonged elimination half-life (t1/2), an increase in blood concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., so it should be avoided to use it in combination. If it cannot be avoided, the blood concentration of theophylline should be measured and the dose should be adjusted. 3 When cyclosporine is used in combination with this product, its blood concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4 When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter, so the combination of the two should be avoided. If it cannot be avoided, the patient's prothrombin time should be closely monitored and the dose adjusted. 5 Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6 This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (t1/2), and possible central nervous system toxicity, so the two should be avoided in combination. If it cannot be avoided, the patient's blood caffeine concentration should be closely monitored and the dose adjusted. 7 Antacids containing aluminum and magnesium can reduce the oral absorption of this product and should not be used together. 8 When this product is used in combination with the non-steroidal anti-inflammatory drug fenbufen, convulsions occasionally occur, so it should not be used in combination with fenbufen.
Specifications	0.2g (based on enoxacin)
Manufacturer	Hainan Hualon Pharmaceutical Co., Ltd.

Enoxacin Gluconate
Manufacturer	Jinzhou Jiutai Pharmaceutical Co., Ltd.

See More Related Drugs

Registered Holders

Hainan Huluwa Pharmaceutical Group Co., Ltd.

China
Active
Dalian Jinyi Pharmaceutical Factory

China
Active
Hainan Zhuoke Pharmaceutical Co., Ltd.

China
Active

See More Registered Holders